PolyPid Ltd. (PYPD)

4.9400 +0.0100 (+0.20%) At close: 04:00PM EDT

PolyPid Ltd.

18 Hasivim Street
Petah Tikva 4959376
Israel
972 7 4719 5700
https://www.polypid.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 59

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Dikla Czaczkes Akselbrad	CEO & Director	347.88k	N/A	1973
Mr. Jonny Missulawin	Chief Financial Officer	186.96k	N/A	1987
Ms. Dalit Hazan	Executive Vice President of R&D and Clinical & Regulatory Affairs	272.38k	N/A	1971
Mr. Ori Warshavsky	Chief Operating Officer - US	340.89k	N/A	1978
Ms. Maria Rubin	Vice President of Operations	N/A	N/A	N/A
Mr. Tal Vilnai	General Counsel & Corporate Secretary	N/A	N/A	N/A
Ms. Rivi Lev-ari	Vice President of Human Resource	N/A	N/A	N/A
Dr. Jean-Marc Hagai Pharm.D.	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Corporate governance

PolyPid Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.